Integra LifeSciences Holdings Co. (NASDAQ:IART) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have earned an average recommendation of “Reduce” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $23.00.

A number of analysts recently weighed in on the stock. Bank of America lowered their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research note on Monday, October 7th. Morgan Stanley began coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price target for the company. Citigroup increased their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, Truist Financial decreased their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th.

Insider Buying and Selling

In other news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the transaction, the executive vice president now owns 56,182 shares in the company, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors have recently added to or reduced their stakes in the business. Blue Trust Inc. increased its holdings in shares of Integra LifeSciences by 100.5% in the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 444 shares during the period. CWM LLC grew its holdings in Integra LifeSciences by 50.8% in the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock valued at $37,000 after purchasing an additional 425 shares during the last quarter. KBC Group NV grew its holdings in Integra LifeSciences by 65.2% in the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after purchasing an additional 1,120 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Integra LifeSciences in the second quarter valued at $114,000. Finally, Northwest Investment Counselors LLC purchased a new stake in shares of Integra LifeSciences in the third quarter valued at $73,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Trading Up 1.0 %

Shares of IART opened at $24.10 on Friday. The company’s fifty day moving average is $21.32 and its 200 day moving average is $23.92. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $45.42. The stock has a market capitalization of $1.86 billion, a PE ratio of -267.78, a P/E/G ratio of 0.84 and a beta of 1.15. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $380.80 million for the quarter, compared to analysts’ expectations of $375.81 million. During the same quarter in the previous year, the business posted $0.76 earnings per share. The business’s revenue was down .4% compared to the same quarter last year. Sell-side analysts expect that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.